289 related articles for article (PubMed ID: 28678626)
1. Optimising use of thiopurines in inflammatory bowel disease.
Dart RJ; Irving PM
Expert Rev Clin Immunol; 2017 Sep; 13(9):877-888. PubMed ID: 28678626
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Serpico MR; Maltz R; Crandall W; Bricker J; Dotson JL; Kim SC; Boyle B
J Pediatr Gastroenterol Nutr; 2018 Sep; 67(3):341-345. PubMed ID: 29601433
[TBL] [Abstract][Full Text] [Related]
4. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
Min MX; Weinberg DI; McCabe RP
J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
Vasudevan A; Con D; De Cruz P; Sparrow MP; Friedman AB; Garg M; Kashkooli S; Gibson PR; van Langenberg DR
Aliment Pharmacol Ther; 2024 Feb; 59(4):504-514. PubMed ID: 38095246
[TBL] [Abstract][Full Text] [Related]
6. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
Johnson CM; Dassopoulos T
Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
[TBL] [Abstract][Full Text] [Related]
7. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo.
Turbayne AK; Sparrow MP
Dig Dis Sci; 2022 Dec; 67(12):5382-5391. PubMed ID: 36242689
[TBL] [Abstract][Full Text] [Related]
10. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
Kiszka-Kanowitz M; Theede K; Mertz-Nielsen A
Scand J Gastroenterol; 2016 Dec; 51(12):1470-1475. PubMed ID: 27686002
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine therapy in inflammatory bowel disease.
Ha C; Dassopoulos T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
[TBL] [Abstract][Full Text] [Related]
13. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
14. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
15. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.
Rahhal RM; Bishop WP
Inflamm Bowel Dis; 2008 Dec; 14(12):1678-82. PubMed ID: 18521913
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease.
Sánchez Rodríguez E; Ríos León R; Mesonero Gismero F; Albillos A; Lopez-Sanroman A
Gastroenterol Hepatol; 2018 Dec; 41(10):629-635. PubMed ID: 30107940
[TBL] [Abstract][Full Text] [Related]
17. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Bermejo F; Aguas M; Chaparro M; Domènech E; Echarri A; García-Planella E; Guerra I; Gisbert JP; López-Sanromán A;
Gastroenterol Hepatol; 2018 Mar; 41(3):205-221. PubMed ID: 29357999
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
[TBL] [Abstract][Full Text] [Related]
19. Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease.
Sheikh M; Nelson-Piercy C; Duley J; Florin T; Ansari A
J Crohns Colitis; 2015 Aug; 9(8):680-4. PubMed ID: 25939351
[TBL] [Abstract][Full Text] [Related]
20. The role and advances of immunomodulator therapy for inflammatory bowel disease.
Nielsen OH; Coskun M; Steenholdt C; Rogler G
Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):177-89. PubMed ID: 25101818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
